Business
TNI BioTech Inc. Announces First Shipment of Lodonal® to The Republic of Panama and The Republic of Malawi
TNI BioTech Inc. Announces First Shipment of Lodonal® to The Republic of Panama and The Republic of Malawi.
About this update from Biostax Corp.
[{"type":"text","content":"\n\n\n\nTNI BioTech Inc. Announces First Shipment of Lodonal® to The Republic of Panama and The Republic of Malawi\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nTNI BioTech Inc. Announces First Shipment of Lodonal® to The Republic of Panama and The Republic of Malawi\nPR Newswire\nORLANDO, Fla, Aug. 27, 2014\n\n\n\nORLANDO, Fla, Aug. 27, 2014 /PRNewswire/ -- TNI BioTech Inc. (OTCQB: TNIB), (\"we\" or the \"Company\") a biotechnology company pioneering the manufacturing and marketing of innovative therapies for autoimmune diseases in emerging nations, today announced it had received payment and will make its first shipments of Lodonal® to the Republic of Panama and The Republic of Malawi in conjunction with our marketing partner, The Brewer Group, Inc. \n\nCommenting on the initial shipments, Noreen Griffin, CEO of TNI BioTech, stated, \"Extensive work has been conducted and funds spent over the last twelve months obtaining local regulatory approval preparing for the launch of Lodonal® in these markets including participation at health conferences, drug dossiers, clinical case studies and training for sales professionals. We are confident that our distributors and sales teams are well positioned to establish Lodonal® as a major competitor in the treatment of cancer and autoimmune diseases in emerging nations. We are looking forward to launching Lodonal® in additional markets in the fourth quarter of 2014.\"   \n\nLodonal® is an active immunotherapy with low dose naltrexone (LDN), an oral medication that works by activating a patient's immune system against HIV/AIDS and tumor cells or by rebalancing the immune system of patients with autoimmune diseases with no toxic side effects. \n\nLodonal® competes in the advanced cancer and autoimmune drug market. Global Industry Analysis, Inc. recently released a comprehensive global report on the Autoimmune Disease Therapeutics market, which stated that the global market for Autoimmune Disease Therapeutics is projected to exceed US$77 billion by the year 2017, driven by t...